Previous 10 | Next 10 |
Syros Pharmaceuticals (NASDAQ: SYRS ): Q1 GAAP EPS of -$0.49 beats by $0.07 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Successfully Completed $70 Million Financing On Track for Multiple Data Readouts for Clinical-Stage Programs in 2019 and 2020 Management to Host Conference Call at 8:30 a.m. ET Today Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control ...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 1, 2019 to rep...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, has closed concurrent underwritten public offerings resulting in proceeds of approximately $70 million. According to the update, the offerings consist of 8,667,333 of its common...
"Purgatory is hell with hope. ” ― Philip José Farmer The biotech sector is off to a very tough start this Wednesday in what feels like a lot of algorithmic trading as the market is flat, and there is not a lot of news around the sector to account for the drop. Just befo...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunities for selective cyclin-dependent...
Syros Pharmaceuticals ( SYRS ) has not been doing well in the market since it peaked at $24.31 per share on July 24, 2017. Excitement over some early preclinical- and clinical-stage results has died down, and two cash raises have pointed out the dilution downside potential of poorly capitalize...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its previously announced concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants ...
Gainers: Vital Therapies (NASDAQ: VTL ) +199% . JMU Limited (NASDAQ: JMU ) +24% . Aehr Test Systems (NASDAQ: AEHR ) +22% . GEE Group (NYSEMKT: JOB ) +19% . ChinaNet Online Holdings (NASDAQ: CNET ) +15% . RumbleON (NASDAQ: RMBL ) +15% . Hancock Jaffe Laboratories (NASDAQ: HJLI )...
Syros Pharmaceuticals (NASDAQ: SYRS ) has priced its public offerings of (i) 8,667,333 common shares and Class A warrants to purchase up to 1,951,844 common shares, at $7.50 per common share and warrant and (ii) 666 shares of Series A convertible preferred stock, convertible into 666,000 c...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...